Literature DB >> 29410491

An expanded immunohistochemical profile of osteoclast-rich undifferentiated carcinoma of the urinary tract.

Salvatore F Priore1, Lauren E Schwartz1, Jonathan I Epstein2.   

Abstract

Osteoclast-rich undifferentiated carcinoma of the urinary tract (ORUCUT) is a rare tumor composed of ovoid to spindle-shaped mononuclear cells with intermixed or focally clustered osteoclast-like giant cells. Previous studies have demonstrated that the mononuclear cells are neoplastic cells, while the giant cells are reactive cells of histiocytic lineage. The association between these tumors and classic urothelial carcinomas suggest that the mononuclear cells are derived from urothelial cells; however, no studies have been conducted to assess the immunohistochemical profile of ORUCUT with more specific urothelial markers. This study identified 21 cases of ORUCUT and performed immunohistochemistry for GATA3, uroplakin II, and thrombomodulin along with pancytokeratin (AE1/3) on all cases. Mononuclear cells stained positive in 20 cases (95%) for GATA3 and 19 cases (90%) for thrombomodulin. None of the mononuclear cells were positive for uroplakin II and only three cases showed focal positivity for AE1/3. The osteoclast-like giant cells were negative for GATA3, uroplakin II, thrombomodulin, and AE1/3, providing additional support to a reactive origin for these cells. Additionally, 15 cases (71%) were associated with either in situ or invasive urothelial carcinoma. This study provides an expanded immunohistochemical profile for ORUCUT and more definitively supports a urothelial origin for this tumor.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29410491     DOI: 10.1038/s41379-018-0012-z

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

1.  Uterine leiomyosarcomas with osteoclast-like giant cells associated with high expression of RUNX2 and RANKL.

Authors:  Mika Terasaki; Yasuhiro Terasaki; Kyoko Wakamatsu; Naomi Kuwahara; Koichi Yoneyama; Rieko Kawase; Keisuke Kurose; Etsuko Toda; Yoko Endo; Shinobu Kunugi; Yusuke Kajimoto; Akira Shimizu
Journal:  Virchows Arch       Date:  2021-01-06       Impact factor: 4.064

Review 2.  Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.

Authors:  Manju Aron
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

Review 3.  Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption.

Authors:  Brendan F Boyce; Jinbo Li; Lianping Xing; Zhenqiang Yao
Journal:  Front Immunol       Date:  2018-09-28       Impact factor: 7.561

4.  Clinical Characteristics and Prognosis of Osteoclast-like Giant Cell Tumors of the Pancreas Compared with Pancreatic Adenocarcinomas: A Population-Based Study.

Authors:  Mingfang Xu; Wei Chen; Dong Wang; Mao Nie
Journal:  Med Sci Monit       Date:  2020-07-27

Review 5.  Unusual Faces of Bladder Cancer.

Authors:  Claudia Manini; José I López
Journal:  Cancers (Basel)       Date:  2020-12-10       Impact factor: 6.639

6.  Poorly differentiated muscle-invasive giant cell tumor of the bladder leads to unfavorable clinical outcome.

Authors:  Foteini Karasavvidou; Lampros Mitrakas; Maria Strataki; Dimitrios Anastasiou; Georgios Koukoulis; Vassilios Tzortzis
Journal:  J Surg Case Rep       Date:  2022-04-11

7.  Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance.

Authors:  Carina Bernardo; Fátima L Monteiro; Inês Direito; Francisco Amado; Vera Afreixo; Lúcio L Santos; Luisa A Helguero
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-08       Impact factor: 5.555

Review 8.  Osteoclasts in Tumor Biology: Metastasis and Epithelial-Mesenchymal-Myeloid Transition.

Authors:  Kemal Behzatoglu
Journal:  Pathol Oncol Res       Date:  2021-04-30       Impact factor: 3.201

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.